Delving into the Latest Updates on Prosetta Biosciences, Inc. with Synapse

概览

疾病领域	数量

神经系统疾病	6
内分泌与代谢疾病	4
感染	4

排名前五的药物类型	数量

化学药	7
小分子化药	3

排名前五的靶点	数量

SOD1(超氧化物歧化酶)	1
TDP43(TAR DNA结合蛋白43)	1
C9orf72	1
MIF(巨噬细胞移动抑制因子)	1

关联

19

项与 Prosetta Biosciences, Inc. 相关的药物

ALS-C9orf72(Prosetta)

靶点

C9orf72

作用机制

C9orf72调节剂

在研机构

Prosetta Biosciences, Inc.

原研机构

Prosetta Biosciences, Inc.

在研适应症

肌萎缩侧索硬化

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

Gram bacteria(Prosetta)

靶点-

作用机制-

在研机构

Prosetta Biosciences, Inc.

原研机构

Prosetta Biosciences, Inc.

在研适应症

革兰氏阴性菌感染 [+1]

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

PAV-174

靶点

MIF

作用机制

MIF抑制剂

在研机构

Prosetta Biosciences, Inc.

原研机构

Prosetta Biosciences, Inc.

在研适应症

阿尔茨海默症

非在研适应症-

最高研发阶段临床前

首次获批国家/地区-

首次获批日期-

100 项与 Prosetta Biosciences, Inc. 相关的临床结果

登录后查看更多信息

0 项与 Prosetta Biosciences, Inc. 相关的专利（医药）

登录后查看更多信息

17

项与 Prosetta Biosciences, Inc. 相关的文献（医药）

2024-12-01·Open Biology

Small molecule protein assembly modulators with pan-cancer therapeutic efficacy

Article

作者: Campi, Thomas W. ; Korth, Carsten ; Yu, Shao Feng ; Aston, Emily ; Michon, Maya ; Andrews, David W. ; Fernandez, Yuniel ; Froehlich, Markus ; Müller-Schiffmann, Andreas ; Prasad, Dharma ; Fabbri, Brad ; Lingappa, Jaisri R. ; Mallesh, Suguna ; Lin, Jim ; Samueli, Erin ; Lu, Ming ; Lingappa, Vishwanath R. ; Nalca, Aysegul ; Lingappa, Anuradha F. ; Solas, Dennis ; Kitaygorodskyy, Anatoliy ; Le, Phuong Uyen ; Rubenstein, James L. ; Anand, Sanjeev K. ; Petrouski, Emma ; Ziari, Niloufar ; Ewald, Connie ; Reed, Jonathan C. ; Dey, Debendranath ; Akintunde, Olayemi

Two structurally unrelated small molecule chemotypes, represented by compounds PAV-617 and PAV-951, with antiviral activity in cell culture against Mpox virus (formerly known as monkeypox virus) and human immunodeficiency virus (HIV) respectively, were studied for anti-cancer efficacy. Each exhibited apparent pan-cancer cytotoxicity with reasonable pharmacokinetics. Non-toxicity is demonstrated in a non-cancer cell line and in mice at doses achieving drug exposure at active concentrations. Anti-tumour properties of both chemotypes were validated in mouse xenografts against A549 human lung cancer and, for one of the chemotypes, against HT-29 colorectal cancer. The targets of these compounds are unconventional: each binds to a different transient, energy-dependent multi-protein complex. Treatment with these compounds alters the target multi-protein complexes in a manner that appears to remove a block, crucial for cancer survival and progression, on a homeostatic linkage between uncontrolled proliferation and apoptosis. These compounds provide starting points for development of novel, next-generation, non-toxic, pan-cancer therapeutics.

2021-10-29·Bioscience Reports4区 · 生物学

Multifunctionality of prostatic acid phosphatase in prostate cancer pathogenesis

4区 · 生物学

Article

作者: Gulati, Mittul ; McAllister, Sean ; Hansen, William J. ; Johansen, Eric ; Hall, Steven C. ; Lingappa, Vishwanath R. ; Alpert, Evgenia ; Gruzman, Arie ; Lin, Ming-Fong ; Lehrer-Graiwer, Joshua ; Akhavan, Armin

AbstractThe role of human prostatic acid phosphatase (PAcP, P15309|PPAP_HUMAN) in prostate cancer was investigated using a new proteomics tool termed signal sequence swapping (replacement of domains from the native cleaved amino terminal signal sequence of secretory/membrane proteins with corresponding regions of functionally distinct signal sequence subtypes). This manipulation preferentially redirects proteins to different pathways of biogenesis at the endoplasmic reticulum (ER), magnifying normally difficult to detect subsets of the protein of interest. For PAcP, this technique reveals three forms identical in amino acid sequence but profoundly different in physiological functions, subcellular location, and biochemical properties. These three forms of PAcP can also occur with the wildtype PAcP signal sequence. Clinical specimens from patients with prostate cancer demonstrate that one form, termed PLPAcP, correlates with early prostate cancer. These findings confirm the analytical power of this method, implicate PLPAcP in prostate cancer pathogenesis, and suggest novel anticancer therapeutic strategies.

2016-12-01·Biology Direct3区 · 生物学

Biochemical and biophysical characterization of cell-free synthesized Rift Valley fever virus nucleoprotein capsids enables in vitro screening to identify novel antivirals

3区 · 生物学

ArticleOA

作者: Hurt, Clarence R ; Broce, Sean ; Freeman, Beverly ; Sato, Tomoharu ; Davis, Christopher J ; Hensley, Lisa ; Pajda, Jacqueline ; Kelleher, Colm A ; Bhadresh, Rami ; Edwards, Katie J ; Karpuj, Marcela V ; Essrich, Christian ; Lingappa, Vishwanath R ; Lehrer-Graiwer, Joshua

BACKGROUNDViral capsid assembly involves the oligomerization of the capsid nucleoprotein (NP), which is an essential step in viral replication and may represent a potential antiviral target. An in vitro transcription-translation reaction using a wheat germ (WG) extract in combination with a sandwich ELISA assay has recently been used to identify small molecules with antiviral activity against the rabies virus.RESULTSHere, we examined the application of this system to viruses with capsids with a different structure, such as the Rift Valley fever virus (RVFV), the etiological agent of a severe emerging infectious disease. The biochemical and immunological characterization of the in vitro-generated RVFV NP assembly products enabled the distinction between intermediately and highly ordered capsid structures. This distinction was used to establish a screening method for the identification of potential antiviral drugs for RVFV countermeasures.CONCLUSIONSThese results indicated that this unique analytical system, which combines nucleoprotein oligomerization with the specific immune recognition of a highly ordered capsid structure, can be extended to various viral families and used both to study the early stages of NP assembly and to assist in the identification of potential antiviral drugs in a cost-efficient manner.REVIEWERSReviewed by Jeffry Skolnick and Noah Isakov. For the full reviews please go to the Reviewers' comments section.

100 项与 Prosetta Biosciences, Inc. 相关的药物交易

登录后查看更多信息

100 项与 Prosetta Biosciences, Inc. 相关的转化医学

登录后查看更多信息

组织架构

使用我们的机构树数据加速您的研究。

登录

或

查看完整样例数据

管线布局

2025年06月01日管线快照

管线布局中药物为当前组织机构及其子机构作为药物机构进行统计，早期临床1期并入临床1期，临床1/2期并入临床2期，临床2/3期并入临床3期

临床前

10

9

其他

登录后查看更多信息

当前项目

药物(靶点)	适应症	全球最高研发状态

Ebola(Prosetta)	埃博拉病毒性疾病更多	临床前
PAV-866	狂犬病更多	临床前
ALS-SOD G93A(Prosetta) ( SOD1 )	肌萎缩侧索硬化更多	临床前
PAV-431	呼吸道合胞体病毒感染更多	临床前
ALS-C9orf72(Prosetta) ( C9orf72 )	肌萎缩侧索硬化更多	临床前